Abbott Laboratories (ABT)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
$108.33-0.42%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
Warn: Primary pillar under pressure — Adjusted EPS growth to about $5.48 per share in 2026: EPS $5.53 vs $5.48 target.
Abbott aims for 6.5% to 7.5% organic sales growth in 2026. Adjusted EPS is guided around $5.48 per share for 2026. The company cleared a major legal risk, reducing uncertainty. Abbott's acquisition of Exact Sciences supports growth in oncology diagnostics.
Abbott faces a lawsuit over PediaSure that could hurt sales and reputation. EPS growth may be pressured by acquisition dilution and soft guidance. Revenue growth below 6.5% would challenge management's targets.
The price is about 15% below our fair value near $112. Analysts expect roughly 14% revenue growth, which is slightly above management's 6.5% to 7.5% organic growth target. Our fair value is 6% below the Street median, reflecting some caution.
Breaks if: EPS falls below $5.12 in FY26
Breaks if: Failure to realize synergies or integration setbacks reported
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a durable compounder with a focus on organic sales growth and adjusted EPS growth. The current thesis state is intact, supported by strong financial performance and management's reaffirmed guidance.
The market currently prices ABT as relatively cheap compared to its peers, with a slight expectations gap. There is a low fragility tier, indicating that the stock is not overly sensitive to negative news at this time.
Fundamentals are expected to remain strong, with management on track to meet its growth targets. However, there is a moderate risk due to the potential for external factors, such as economic conditions, to impact performance.
The long-term thesis hinges on the company's ability to maintain its guidance and deliver on its growth targets. Additionally, the performance of sector peers and broader economic indicators will play a crucial role in shaping future outcomes.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. Abbott Laboratories launched a new infant formula product, Similac 360 Total Care. This expansion in the product portfolio is expected to drive higher revenue in its nutrition segment. The latest earnings beat also supports the improved outlook.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Legal rulings cause significant financial or reputational damage
Breaks if: Organic revenue growth falls below 6.5% in FY26
Overall, ABT's outlook appears stable, but it must navigate potential risks in the near term. Not investment advice.